|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
Agents identified as cholesterol inhibitors in
accordance with this method can block the internalization of plasma membrane
cholesterol from entering the cell interior thereby causing cholesterol to
accumulate in the plasma membrane and promoting cholesterol efflux and
stimulating reverse cholesterol transport in various body cells. These agents are expected to slow the
development of atherosclerosis.
Agents identified as inhibitors can also block the internalization of
plasma membrane cholesterol in intestinal enterocytes,
thereby preventing dietary cholesterol absorption. Such agents can also slow down the
accumulation of amyloid beta-peptides in the brain,
thereby slowing down the symptoms of Alzheimer’s disease. Accordingly, test agents identified as
cholesterol inhibitors with this assay are expected to be useful in
preventing and treating cardiovascular and neurodegenerative diseases
associated with over accumulation of cholesterol in cells. Such agents are expected to be useful in
the treatment of Niemann Pick type C disease, an autosomal recessive, neurovisceral
disorder that affects children. These findings are claimed in the issued United States
Patent No. 7,049,086. We are seeking
an industrial partner who is interested in their further refinement and
commercialization. (Ref: J161) |
||
|
|
|
|
|
|
|
|
«Technology Transfer Office : Sponsored Projects : Dartmouth College |
|||
|
|
||||
|
11 Rope Ferry Road #6210 |
||||
|
Hanover, NH 03755-1404 |
Phone: (603) 646-3027 |
|||
|
|
|
|
Fax: (603) 646-3670 |
|